Pharmacologic treatments for gestational diabetes mellitus show varying impacts on glucose and neonatal outcomes
Comparing different medications to manage gestational diabetes during pregnancy
This network meta-analysis evaluated several pharmacologic treatments for patients with gestational diabetes mellitus, including insulin, bi…
New data compares several types of medication for gestational diabetes, highlighting insulin's safety and specific risks associated with oth…
SGLT2 inhibitor use associated with increased diabetic ketoacidosis risk, especially with elevated HbA1c
New review shows SGLT2 drugs raise DKA risk when blood sugar is high
This meta-analysis of observational and randomized trials found SGLT2 inhibitor use is associated with an increased risk of diabetic ketoaci…
A big review of many studies found that medicines for diabetes called SGLT2 inhibitors can increase the chance of a serious condition called…
SGLT-2 inhibitors reduce heart failure hospitalization and stroke in patients with acute coronary syndrome
SGLT-2 Drugs Cut Stroke Risk After Heart Attack
This meta-analysis evaluated SGLT-2 inhibitors in patients hospitalized for acute coronary syndrome with additional risk factors. The analys…
New research shows that a specific diabetes drug can lower the risk of stroke and heart failure in people recovering from a heart attack.
Mini-review links insulin to worse COVID-19 outcomes in type 2 diabetes patients
Diabetes Meds Do Not Stop COVID-19
A mini-review of observational studies in patients with type 2 diabetes mellitus found that insulin was linked to worse COVID-19 outcomes, w…
Recent research proves that common diabetes pills do not protect you from getting sick or dying from a virus infection.
Network meta-analysis of novel antidiabetic drugs in T2DM with CKD shows sotagliflozin, empagliflozin, and semaglutide rank highest for cardiovascular and renal outcomes
A Clear Winner Emerges for Diabetes Patients with Kidney Disease
This network meta-analysis evaluated novel antidiabetic drugs, including SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors, i…
For millions managing both diabetes and kidney disease, new research clarifies which medications offer the best protection for their heart a…